Efficacy and safety of lenvatinib in patients with recurrent hepatocellular carcinoma after liver transplantation

Abstract

Lenvatinib showed consistent efficacy and toxicity profiles in patients with post-LT HCC recurrence that were comparable to those reported from previous studies among non-LT HCC patients. The baseline ALBI grade correlated with better OS in post-LT lenvatinib-treated patients.